Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 475 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Menopausal Women Clear all
Terminated No phase listed Observational Accepts healthy volunteers

Screening Evaluation for Women With Postpartum Depression

NCT00056901
View directory record Official record
Conditions
Postpartum Depression, Depression
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
20 Years to 45 Years · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Oct 25, 2026, 9:48 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity

NCT07218445
View directory record Official record
Conditions
Obesity, Menopause Hot Flashes
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
46 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 9:48 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women

NCT01475513
View directory record Official record
Conditions
Insulin Sensitivity, Cardiovascular Risk, Perimenopausal Disorder
Interventions
Ortho Cyclen®
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 25, 2026, 9:48 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.

NCT00323635
View directory record Official record
Conditions
Urinary Incontinence
Interventions
tolterodine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 25, 2026, 9:48 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Nuvigil on Fatigue

NCT01460628
View directory record Official record
Conditions
Menopause
Interventions
Armodafinil
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 25, 2026, 9:48 AM EDT
Completed No phase listed Observational

Ovarian Follicle Function in Patients With Primary Ovarian Failure

NCT00001275
View directory record Official record
Conditions
Amenorrhea, Hypoaldosteronism, Hypogonadism, Infertility, Premature Ovarian Failure
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 42 Years · Female only
Enrollment
1,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 25, 2026, 9:48 AM EDT
Terminated Phase 1 Interventional Results available

Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.

NCT02936206
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, Tamoxifen
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 25, 2026, 9:48 AM EDT
Terminated Early Phase 1 Interventional

GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors

NCT03185169
View directory record Official record
Conditions
Genitourinary Abnormality, Breast Cancer Female, Vaginal Abnormality, Urinary Tract Infections, Dyspareunia, Dysuria
Interventions
Replens and coconut oil
Combination Product
Lead sponsor
Alta Bates Summit Medical Center
Other
Eligibility
Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 25, 2026, 9:48 AM EDT
Recruiting Phase 2 Interventional

Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery

NCT06450873
View directory record Official record
Conditions
Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma
Interventions
Coriolus Versicolor Extract, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 25, 2026, 9:48 AM EDT
Completed Not applicable Interventional Results available

Addressing Sexual Concerns in Breast Cancer: Patient Intervention Study

NCT03624972
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Starting the Conversation Video, Sexual and Menopausal Health Resources
Behavioral
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 25, 2026, 9:48 AM EDT
Recruiting Not applicable Interventional

Satavari and Ashoka for Menopause (SAM) Study

NCT07861295
View directory record Official record
Conditions
Menopause
Interventions
Ashoka Bark and Shatavari, Placebo
Dietary Supplement · Other
Lead sponsor
Vidya USA Corporation
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Port Richey, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 9:48 AM EDT
Terminated Phase 3 Interventional Results available

STRIDE - STimulating Immune Response In aDvanced brEast Cancer

NCT00925548
View directory record Official record
Conditions
Breast Cancer
Interventions
Tecemotide (L-BLP25) and Hormonal Treatment, Placebo of tecemotide (L-BLP25) and Hormonal Treatment, cyclophosphamide, sodium chloride (NaCl)
Biological · Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Hickory, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 25, 2026, 9:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

"The Effects of Caffeine on Overactive Bladder Symptoms and Mental Health in Postmenopausal Women"

NCT02180048
View directory record Official record
Conditions
Overactive Bladder, Caffeine, Menopause
Interventions
400 mg of caffeine/day (Two 200mg pills/day), 200 mg of caffeine/day (One 200mg pill and one placebo pill), Two placebo pills/day
Dietary Supplement
Lead sponsor
Loma Linda University
Other
Eligibility
58 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 25, 2026, 9:48 AM EDT
Terminated Phase 3 Interventional Results available

Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer

NCT00429403
View directory record Official record
Conditions
Breast Cancer
Interventions
Goserelin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 46 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 25, 2026, 9:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Bioequivalence of Fezolinetant Formulations in Healthy Female Participants

NCT04277624
View directory record Official record
Conditions
Healthy Volunteers
Interventions
fezolinetant - test formulation, fezolinetant - reference formulation
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 25, 2026, 9:48 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Impact of Estradiol on Endothelial Function in Peri-Menopausal Women

NCT04255160
View directory record Official record
Conditions
Perimenopause, Vasodilation, Estrogen
Interventions
Estradiol (mylan or vivelle dot patch), Placebo
Drug · Other
Lead sponsor
University of Delaware
Other
Eligibility
40 Years to 58 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 25, 2026, 9:48 AM EDT
Completed Phase 3 Interventional Results available

Topical DHEA Against Vaginal Atrophy

NCT01846442
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Placebo, DHEA (0.25%), DHEA (0.5%), DHEA (1.0%)
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Cleveland, Ohio • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Oct 25, 2026, 9:48 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

NCT00612742
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
testosterone gel, placebo gel
Drug
Lead sponsor
BioSante Pharmaceuticals
Industry
Eligibility
50 Years and older · Female only
Enrollment
3,656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
141
States / cities
Birmingham, Alabama • Hoover, Alabama • Huntsville, Alabama + 116 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 25, 2026, 9:48 AM EDT
Completed Phase 2 Interventional Results available

Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003

NCT00958334
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex®
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Phoenix, Arizona • San Diego, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 25, 2026, 9:48 AM EDT
Completed Phase 2 Interventional

Hormone Replacement in Menopausal Women With Epilepsy

NCT00027209
View directory record Official record
Conditions
Menopause, Epilepsy
Interventions
prempro
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
0 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2006 · Synced Oct 25, 2026, 9:48 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Effect of 1,25-dihydroxyvitamin D3, Treatment on Insulin Secretion and Muscle Strength in Pre-diabetic Persons

NCT04286529
View directory record Official record
Conditions
Pre-Diabetic
Interventions
Calcitriol capsules, Oral Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years to 45 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Oct 25, 2026, 9:48 AM EDT
Completed Not applicable Interventional Results available

HIRREM Hot Flashes Study

NCT03512002
View directory record Official record
Conditions
Vasomotor Symptoms, Hot Flashes, Menopause
Interventions
HIRREM, Continued Current Care
Device · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 25, 2026, 9:48 AM EDT
Recruiting Phase 1 Interventional

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

NCT06139107
View directory record Official record
Conditions
Breast Cancer
Interventions
Abemaciclib, Letrozole
Drug
Lead sponsor
Mridula George, MD
Other
Eligibility
60 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
4
States / cities
Belleville, New Jersey • Livingston, New Jersey • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 25, 2026, 9:48 AM EDT
Completed Phase 3 Interventional Results available

Heartland Osteoporosis Prevention Study

NCT02186600
View directory record Official record
Conditions
Osteopenia
Interventions
Calcium Carbonate, Vitamin D3, Risedronate, Bone-loading exercises
Drug · Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 25, 2026, 9:48 AM EDT